abstract: Spectrum of (FDG-PET/CT) fluorodeoxyglucose-positron emission tomography/computed tomography and magnetic resonance imaging findings of ovarian tumors.

Abstract

The purpose of this article is to review fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) and magnetic resonance imaging (MRI) findings in a variety of benign, malignant, and borderline malignant ovarian tumors. It is advantageous to become familiar with the wide variety of FDG-PET/CT findings of this entity. Benign ovarian tumors generally have faint uptake, whereas endometriomas, fibromas, and teratomas show mild to moderate uptake. Malignant ovarian tumors generally have intense uptake, whereas tumors with a small solid component often show minimal uptake.

PET/CT imaging in gynecologic malignancies: A critical overview of its clinical impact and our retrospective single center analysis 10.1016/j.critrevonc.2011.10.002 : Critical Reviews in Oncology

  A growing body of evidence defines PET/CT as one of the most powerful tools for tumor, nodal and metastasis (TNM) cancer staging both in pre-treatment and in post treatment follow-up settings.

At any phase of cancer evaluation, detection of metastasis represents one of the most critical impediments to the cure of tumor; traditional diagnostic imaging modalities, such as computed tomography (CT), are frequently found to inadequately stage the tumor, based on subsequent outcomes.. ...

Highlights

► FDG-PET/CT is a valid instrument for the detection of recurrent or metastatic gynaecologic tumours.
► Evidence corroborates FDG-PET/CT's role in ovarian cancer in monitoring response to chemotherapy.
► In uterine cervical carcinoma, FDG-PET/CT is more sensitive than MRI for detecting nodal metastases.
► Retrospective analysis of 116 patients showed FDG-PET/CT was principally useful in the setting of suspected recurrence.